Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
PONTE VEDRA, Fla., Nov. 30, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to